EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.

中文翻译：

---

常规临床实践的证据：EMPRISE为CVOT提供了新的视角。

EMPA-REG OUTCOME被国际准则认可为具有里程碑意义的研究，表明依帕列净对2型糖尿病（T2D）和心血管疾病患者具有明显的心脏保护作用。为了评估Empagliflozin在常规临床实践中的影响，正在进行的EMPRISE研究正在收集现实世界的证据，以比较Empagliflozin与DPP-4抑制剂之间的有效性，安全性和健康经济结果。最近发表了一项计划的EMPRISE中期分析，证实了依帕列净治疗心力衰竭的住院患者数量显着减少。在这篇评论文章中，我们将在临床证据和临床指南的背景下讨论新数据，因为临床医生在处理T2D患者的心血管风险方面经验丰富。